Overview
Trelegy Ellipta is a combination inhalation powder containing Fluticasone furoate (100 mcg), Umeclidinium (62.5 mcg), and Vilanterol (25 mcg). It is prescribed for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults. This triple therapy combines a corticosteroid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-agonist (LABA) to reduce inflammation, relax airway muscles, and improve breathing.





